“Prenatal therapies are the next disruptive technologies in health care, which will advance and shape the future of patient care in the 21st century,” said Graça Almeida-Porada, a professor at the Fetal Research and Therapy Center of the Wake Forest Institute for Regenerative Medicine in Winston-Salem, North Carolina. At the American Society of Gene & Cell Therapy (ASGCT) annual meeting in Baltimore on May 5, 2024, Almeida-Porada introduced the first presentation of the scientific symposium “Prospects for Prenatal Gene and Cell Therapy.” Read More
New treatment options for treating Mycobaterium abscessus infections are needed. Previous findings had identified the leucyl-tRNA synthetase inhibitor MRX-6038 to have significant activity against M. abscessus. The aim of this new study was to focus on the activity of MRX-5, the oral prodrug of MRX-6038, both in vivo and in vitro. Read More
Recent findings discovered a mutation in the METTL23 gene, which encodes methyltransferase-like protein 23, in a pedigree of normal-tension glaucoma (NTG). The aim of researchers from the Institute for Vision Research, The University of Iowa Roy J and Lucille A Carver College of Medicine was to confirm an association of mutations in this gene with NTG. Read More
The Global Health Innovative Technology (GHIT) Fund has announced a total investment of approximately ¥1.64 billion (US$10.8 million) in four projects for the development of new drugs for malaria and neglected tropical diseases. Read More
Astrazeneca AB has disclosed CX3C chemokine receptor 1 (CX3CR1; CMKBRL1; GPR13) antagonists reported to be useful for the treatment of heart failure, among others. Read More
The recent cyberattack on Change Healthcare, a part of the Unitedhealth Group, crippled reimbursement claims processing for thousands of providers for several weeks and potentially exposed troves of patient data. Congressional committees are investigating the attack, its scope, and Unitedhealth’s response. Please take a few minutes to fill out this short survey to help BioWorld understand how your company is responding to these threats. You can click through to the questions here. Read More
Researchers from the Icahn School of Medicine at Mount Sinai and affiliated organizations presented the discovery and preclinical characterization of MS-8535, a novel spindlin-1 (SPIN1) inhibitor being developed as chemical tool anticancer agent. Read More
Nanite Inc. has been awarded a $1.8 million grant by the Bill & Melinda Gates Foundation to design and optimize polymeric delivery vehicles to deliver DNA-encoded therapeutics. Read More
Researchers at F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have synthesized 3C-like proteinase (3CLpro, Mpro) (coronavirus) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome infections. Read More
Norroy Bioscience Co. Ltd. has identified conjugates comprising fibroblast activation protein α (FAP)-targeting agents covalently linked to cytotoxic drugs or unlabeled or radiolabeled imaging agents through a linker acting as FAP ligands reported to be useful for diagnosis and treatment of cancer expressing FAP. Read More
Avicenna Biosciences Inc. has introduced an extension to its machine learning (ML) technology platform to enhance medicinal chemistry and expedite clinical-stage drug discovery. Read More
Researchers at Biogen Inc. and Broad Institute Inc. have divulged glycogen synthase kinase-3α (GSK3A; GSK-3α) inhibitors reported to be useful for the treatment of cancer, neurological and metabolic diseases. Read More
Maze Therapeutics Inc. has described sodium-dependent neutral amino acid transporter B(0)AT1 (SLC6A19) inhibitors reported to be useful for the treatment of phenylketonuria, metabolic syndrome, chronic kidney disease and metabolic diseases. Read More
Researchers from Sichuan Baili Pharmaceutical Co. Ltd. and Systimmune Inc. presented preclinical data for the novel CD33-targeting antibody-drug conjugate (ADC) being evaluated for the treatment of hematologic malignancies. Read More
